Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|December 2, 2018
- Pharmaceutical Technology-12-02-2018
- Volume 42
- Issue 12
Mobile App for Supply-Chain Traceability
Adents' DispaX offers improved supply-chain traceability for pharmaceutical warehouses, wholesalers, distributors, and dispensers such as pharmacies and hospitals.
DispaX is a mobile application from Adents developed for pharmaceutical warehouses, wholesalers, distributors, and dispensers such as pharmacies and hospitals for improved supply-chain traceability.
The solution offers three ways to search data: scanning a label, entering a serial or delivery number, or entering a lot number. The application allows all supply chain stakeholders to verify, decommission, and aggregate serialized products at various stages of the supply chain and complies with local regulations in a number of geographies worldwide, according to the company. The application enables users to query by lot, delivery number, serial number, and levels up and down the hierarchy tree. Features include the ability to see all details of an item, navigate up and down parent-child aggregation relationships, manage the products picking, and view shipment history.
Articles in this issue
almost 8 years ago
Sterile, Integrated Hood and Mask for Larger Heads and Hairstylesalmost 8 years ago
Scaling Up and Launching Solid-Dosage Drugsalmost 8 years ago
Developing and Manufacturing Transdermal Patchesalmost 8 years ago
Spray Film Provides Alternative to Patchesalmost 8 years ago
Improving Production: How IT, OT, and Quality Can Collaboratealmost 8 years ago
Manufacturing Considerations for Transdermal Delivery Systemsalmost 8 years ago
Investigation Timeliness vs. Thoroughness: Finding the Right Balancealmost 8 years ago
Microbial Identification Strategies for Bioburden Controlalmost 8 years ago
Fighting Bacterial Resistance with Biologicsalmost 8 years ago
The Key Word: QualityRelated to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.